Abstract
Although mRNA vaccines have become widely used, there are many issues remaining with them, such as temperature stability and anaphylaxis. Viral vector vaccines are highly stable because they are based on DNA, the genetic information forming the basis of antigenic proteins. Adenovirus vector vaccines were approved during the COVID-19 pandemic, however, quality issues subsequently led to declining demand. Alternatively, adeno-associated virus（AAV） vectors have low pathogenicity, immunogenicity, and cytotoxicity and are currently one of the most widely studied vectors for gene therapy. In this article, we will explain the standards for AAV vectors to be used as a new modality to compensate for the disadvantages of mRNA vaccines, including efforts to improve purification technology and quality.
